Source: European journal of clinical pharmacology. Unidade: FM
Subjects: POLIMORFISMO, FÁRMACOS (SISTEMA NERVOSO PERIFÉRICO), TABAGISMO, CITOCROMO P-450, GENÓTIPOS, FARMACOGENÉTICA
ABNT
TOMAZ, Paulo Roberto Xavier et al. Cytochrome P450 2A6 and 2B6 polymorphisms and smoking cessation success in patients treated with varenicline. European journal of clinical pharmacology, v. 75, n. 11, p. 1541-1545, 2019Tradução . . Disponível em: https://doi.org/10.1007/s00228-019-02731-z. Acesso em: 26 abr. 2024.APA
Tomaz, P. R. X., Kajita, M. S., Santos, J. R., Scholz, J., Abe, T. O., Gaya, P. V., et al. (2019). Cytochrome P450 2A6 and 2B6 polymorphisms and smoking cessation success in patients treated with varenicline. European journal of clinical pharmacology, 75( 11), 1541-1545. doi:10.1007/s00228-019-02731-zNLM
Tomaz PRX, Kajita MS, Santos JR, Scholz J, Abe TO, Gaya PV, Krieger JE, Pereira AC, Santos PCJL. Cytochrome P450 2A6 and 2B6 polymorphisms and smoking cessation success in patients treated with varenicline [Internet]. European journal of clinical pharmacology. 2019 ; 75( 11): 1541-1545.[citado 2024 abr. 26 ] Available from: https://doi.org/10.1007/s00228-019-02731-zVancouver
Tomaz PRX, Kajita MS, Santos JR, Scholz J, Abe TO, Gaya PV, Krieger JE, Pereira AC, Santos PCJL. Cytochrome P450 2A6 and 2B6 polymorphisms and smoking cessation success in patients treated with varenicline [Internet]. European journal of clinical pharmacology. 2019 ; 75( 11): 1541-1545.[citado 2024 abr. 26 ] Available from: https://doi.org/10.1007/s00228-019-02731-z